From Bench to Bedside: Translational Breakthroughs in Castration-Resistant Prostate Cancer Research
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 931
Special Issue Editor
Interests: castration-resistance prostate cancer; advanced prostate cancer; androgen receptor; androgen receptor cistrome; epigenetic therapy; lineage plasticity; translational research
Special Issue Information
Dear Colleagues,
This Special Issue, "From Bench to Bedside: Translational Breakthroughs in Castration-Resistant Prostate Cancer Research" , seeks to provide an overview of the significant strides made in CRPC. Prostate cancer is the second most diagnosed malignancy and the fifth leading cause of cancer death among men globally, underscoring the urgent need for advanced therapeutic strategies. Despite this grim statistic, the last decade has been witness to a revolution in prostate cancer treatment marked by rapid advances, e.g., second-generation androgen pathway inhibitors, and improved survival rates.
This Special Issue will present cutting-edge translational research that bridges experimental science and clinical application, focusing on the persistent challenge of CRPC. Contributions should detail the progress in this field, from identifying molecular targets in the lab to developing novel therapies that enhance patients' quality of life and survival. We welcome submissions detailing innovative diagnostic approaches, targeted therapies, immunotherapies, antibody–drug conjugates (ADCs), and strategies for overcoming drug resistance.
Researchers are invited to share their findings on the biology of CRPC, particularly new insights into its development and progression, and the translation of these findings into clinical practice. This Special Issue aims to be a testament to the collaborative efforts of scientists and clinicians who are turning the tide against prostate cancer, offering hope through their commitment to research that culminates in saving lives.
Dr. Wanting Han
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- castration-resistance prostate cancer
- CRPC
- emerging therapies
- translational breakthrough
- therapeutic strategies
- biomarker
